Sesen Bio's EBIT is $49M, below the Healthcare sector average of $23B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2025
Trailing 12 months ending Sep 30, 2025
As of the most recent data (September 2025), SESN shows a EBIT of $49M. That compares with $-41M in the prior-year period — up 218.0% year over year. That is below the Healthcare sector average of $23B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, SESN's EBIT is now $49M (was $-41M) — a 218.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Sesen Bio is outperforming or lagging.
The Healthcare sector average EBIT is about $23B. Sesen Bio is at $49M, which is lower that average. That is roughly 99.8% below the sector mean. Use the comparison chart on this page to see how SESN stacks up against individual peers as well.
Tracking SESN's ebit over time shows whether Sesen Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $49M That compares with $-41M in the prior-year period — up 218.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has Sesen Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $49M) with ownership activity and broader fundamentals.